AC Immune SA [NASDAQ: ACIU] jumped around 0.03 points on Wednesday, while shares priced at $2.93 at the close of the session, up 1.03%.
AC Immune SA stock is now -13.31% down from its year-to-date (YTD) trading value. ACIU Stock saw the intraday high of $2.99 and lowest of $2.815 per share. The company’s 52-week high price is 4.00, which means current price is +104.90% above from all time high which was touched on 10/29/25.
Compared to the average trading volume of 286.67K shares, ACIU reached a trading volume of 159753 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about AC Immune SA [ACIU]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACIU shares is $9.04 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACIU stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for AC Immune SA shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 31, 2024. The new note on the price target was released on February 01, 2019, representing the official price target for AC Immune SA stock.
The Price to Book ratio for the last quarter was 3.29, with the Price to Cash per share for the same quarter was set at 1.38.
How has ACIU stock performed recently?
AC Immune SA [ACIU] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.09. With this latest performance, ACIU shares dropped by -16.76% in over the last four-week period, additionally plugging by 72.86% over the last 6 months – not to mention a rise of 8.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACIU stock in for the last two-week period is set at 43.69, with the RSI for the last a single of trading hit 0.27, and the three-weeks RSI is set at 0.28 for AC Immune SA [ACIU]. The present Moving Average for the last 50 days of trading for this stock 3.14, while it was recorded at 2.96 for the last single week of trading, and 2.31 for the last 200 days.
AC Immune SA [ACIU]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AC Immune SA [ACIU] shares currently have an operating margin of -1667.53%. AC Immune SA’s Net Margin is presently recorded at -1642.99%.
AC Immune SA (ACIU) Capital Structure & Debt Analysis
According to recent financial data for AC Immune SA. ( ACIU), the Return on Equity (ROE) stands at -72.72%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -33.51%, reflecting the company’s efficiency in generating profits from its assets. Additionally, AC Immune SA’s Return on Invested Capital (ROIC) is -101.94%, showcasing its effectiveness in deploying capital for earnings.
AC Immune SA (ACIU) Efficiency & Liquidity Metrics
Based on AC Immune SA’s (ACIU) latest financial statements, the Debt-to-Equity Ratio is 0.07%, indicating its reliance on debt financing relative to shareholder equity.
AC Immune SA (ACIU) Efficiency & Liquidity Metrics
From an operational efficiency perspective, AC Immune SA. (ACIU) effectively leverages its workforce, generating an average of -$492093.02 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.16% and a Quick Ratio of 1.16%, indicating strong ability to cover short-term liabilities.
Earnings analysis for AC Immune SA [ACIU]
With the latest financial reports released by the company, AC Immune SA posted -0.16/share EPS, while the average EPS was predicted by analysts to be reported at -0.19/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.03. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACIU.
Insider trade positions for AC Immune SA [ACIU]
There are presently around $24.85%, or 40.08%% of ACIU stock, in the hands of institutional investors. The top three institutional holders of ACIU stocks are: BVF INC/IL with ownership of 18.83 million shares, which is approximately 18.9201%. BLACKROCK INC., holding 2.61 million shares of the stock with an approximate value of $$10.4 million in ACIU stocks shares; and BLACKROCK INC., currently with $$7.21 million in ACIU stock with ownership which is approximately 1.8159%.
